NCT05900778 Implementation of a HABIT-ILE Intervention at William Lennox Neurological Hospital (NeuREHA)
| NCT ID | NCT05900778 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Université Catholique de Louvain |
| Condition | Acquired Brain Injury |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-06-10 |
| Primary Completion | 2024-12-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-06-10 with a primary completion date of 2024-12-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Using a randomized controlled trial design, in an hospital environment, possible changes induced by the "Hand-arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)" treatment program will be investigated in functional activities of daily living, motor and cognitive assessment of children with acquired brain injury.
Eligibility Criteria
Inclusion Criteria: * children with acquired brain injury of school * age 5 to 18 years inclusive Exclusion Criteria: * Unstable seizure * programmed botulinum toxin or orthopedic surgery in the 6 months previous to the intervention, during intervention period or 3months after the intervention time * Severe visual or cognitive impairments likely to interfere with intervention or testing session completion
Contact & Investigator
Yannick Bleyenheuft, Professor
PRINCIPAL INVESTIGATOR
Insititue of Neurosciences, UCLouvain
Frequently Asked Questions
Who can join the NCT05900778 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 18 Years, studying Acquired Brain Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05900778 currently recruiting?
Yes, NCT05900778 is actively recruiting participants. Contact the research team at yannick.bleyenheuft@uclouvain.be for enrollment information.
Where is the NCT05900778 trial being conducted?
This trial is being conducted at Ottignies-Louvain-la-Neuve, Belgium, Brussels, Belgium, Brussels, Belgium.
Who is sponsoring the NCT05900778 clinical trial?
NCT05900778 is sponsored by Université Catholique de Louvain. The principal investigator is Yannick Bleyenheuft, Professor at Insititue of Neurosciences, UCLouvain. The trial plans to enroll 40 participants.